1. Akebia Therapeutics Inc. Akebia and Mitsubishi Tanabe Pharma announce collaboration to develop and commercialize vadadustat in Asia [media release]. 14 Dec 2015. https://akebia.com/.
2. Zuk A, Si Z, Loi S, et al. Preclinical characterization of vadadustat (AKB-6548), an oral small molecule hypoxia inducible factor prolyl-4-hydroxylase inhibitor, for the potential treatment of renal anemia [abstract no. SA-OR037]. J Am Soc Nephrol. 2019;30:90.
3. Sanghani NS, Haase VH. Hypoxia-inducible factor activators in renal anemia: current clinical experience. Adv Chronic Kidney Dis. 2019;26(4):253–66.
4. Mitsubishi Tanabe Pharma Corporation. Manufacturing and marketing approval of VAFSEO® tablets (HIF-PH inhibitor, vadadustat) for renal anemia in Japan [media release]. 29 Jun 2020. http://www.mt-pharma.co.jp.
5. Mitsubishi Tanabe Pharma Corporation. Vadadustat (VAFSEO tablets): Japanese prescribing information. 2020. https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/400315_39990D3F1020_1_01. Accessed 21 Jul 2020.